Related Experiment Videos
Human pharmacokinetics of tiludronate
L N Sansom1, J Necciari, J F Thiercelin
1School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Bone
|November 1, 1995
Summary
Tiludronate, a bisphosphonate for bone disorders, shows low oral absorption influenced by food. Its pharmacokinetics are similar to other bisphosphonates, but with higher bioavailability than clodronate or pamidronate.
Area of Science:
- Pharmacology
- Bone Metabolism
- Drug Absorption
Background:
- Tiludronate is a bisphosphonate used for metabolic bone disorders.
- Its pharmacokinetic properties are crucial for understanding its efficacy and safety.
- Previous studies indicate low and variable oral absorption for bisphosphonates.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of tiludronate.
- To compare tiludronate's absorption and disposition with other bisphosphonates.
- To assess potential drug interactions and factors affecting tiludronate's bioavailability.
Main Methods:
- Analysis of oral absorption, bioavailability, protein binding, and elimination pathways.
- In vitro studies on biotransformation and enzyme interactions.
- Drug interaction studies with NSAIDs and digoxin.
Main Results:
- Absolute oral bioavailability is approximately 6%, with significant inter- and intra-subject variability.
- Absorption increases at doses >400 mg and decreases with food/dairy intake.
- Tiludronate is highly protein-bound (~90%) and not significantly metabolized.
- Elimination half-life is 40-60 hours in normal renal function, prolonged in renal impairment.
- Renal clearance is dose-independent, suggesting glomerular filtration.
- About 50% of absorbed dose binds to bone.
- Minimal drug interactions observed, except minor changes with indomethacin.
Conclusions:
- Tiludronate exhibits pharmacokinetic characteristics typical of bisphosphonates, including high polarity and bone binding.
- Its oral bioavailability is higher than clodronate and pamidronate.
- Food significantly impacts absorption, necessitating careful administration timing.
- Further studies are needed to correlate pharmacokinetic properties with clinical outcomes.